Compare · BSTC vs DRNA
BSTC vs DRNA
Side-by-side comparison of BioSpecifics Technologies Corp (BSTC) and Dicerna Pharmaceuticals, Inc. (DRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSTC and DRNA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for BSTC).
- Company
- BioSpecifics Technologies Corp
- Dicerna Pharmaceuticals, Inc.
- Price
- -
- $38.23+0.61%
- Market cap
- -
- $2.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 14
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest BSTC
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form 1 filed
- Endo Completes Acquisition of BioSpecifics
- Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
- WeissLaw LLP Reminds BSTC, DNKN, NAV, and PNM, Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, Endurance International Group Holdings, Inc., GCI Liberty, Inc., Liberty Broadband Corporation, and PNM Resources, Inc.
- WeissLaw LLP Reminds BSTC, PNM, and DNKN Shareholders About Its Ongoing Investigations
- Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
- BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company